Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial
在转移性去势抵抗性前列腺癌患者接受多西他赛和阿比特龙治疗后出现疾病进展的情况下，新型雄激素受体抑制剂氘代沙鲁胺的疗效：来自随机 III 期 HC-1119-04 试验的结果
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-026-02618-3
Wu, Junlong; Li, Xinghai; Gu, Chengyuan; Hua, Lixin; Liu, Ranlu; Li, Jun; Qiu, Mingxing; Guo, Jianming; Dong, Haiying; Ji, Zhigang; Xie, Liping; Zhu, Shaoxing; Zhang, Xuhui; Chen, Peng; Jiang, Shusuan; Sun, Zhongquan; Xu, Danfeng; Chen, Hui; Shi, Benkang; Wang, Yujie; Pu, Jinxian; Perabo, Frank; Chen, Yuanwei; Ye, Dingwei
